منابع مشابه
Lack of reversibility for NOACs
Dear Editor, I read with interest the recent discussion on the ENGAGE-AF trial written by Kaba et al. The authors provide a comprehensive discussion of the novel oral anticoagulant (NOAC), Edoxaban. However, it is important to remind the readers that although NOACs are being promoted as first line for stroke prevention in atrial fibrillation, there is considerable risk of bleeding associated wi...
متن کاملResponse to ‘Lack of reversibility for NOACs’
Dear Editor, The points raised by Al-Kindi are well made and we accept concerns raised about the current lack of reliable reversal agents for the NOACs. This is also relevant to surgeons and interventionists, not least when performing percutaneous ablation therapy for atrial fibrillation, which is now routinely undertaken without discontinuing warfarin in those patients who are on this therapy....
متن کاملNOACs; Friend or Foe?
New oral anticoagulants (NOAC’s) are becoming more popular as antithrombotic agents for the prevention of venous thromboembolism in atrial fibrillation and as prophylaxis in hip and knee surgery. With simple administration, rapid onset, few drug interactions and the absence of coagulation monitoring, NOAC’s appear as a friend in the prevention of thromboembolic events. Undoubtedly patients woul...
متن کاملThe Value Premium: Systematic Risk due to Costly Reversibility, Errors in Expectation, or Lack of Recognition?
Recent theoretical research in finance argues that the value premium is due to a systematic risk factor attributable to costly reversibility. In testing the costly reversibility hypotheses, the study recognises that there are a number of other possible explanations that need to be controlled for. Behavioural finance literature suggests that the value premium may be driven by errors in expectati...
متن کاملNOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
Atrial fibrillation is a heart arrhythmia associated with increased risk for ischemic stroke. Vitamin K antagonists were developed to decrease a patient's clotting risk; however, these medications require therapeutic monitoring and have several drug interactions. Novel oral anticoagulants (NOACs) were developed as an alternative to vitamin K antagonists and several studies have evaluated the ab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Global Cardiology Science and Practice
سال: 2014
ISSN: 2305-7823
DOI: 10.5339/gcsp.2014.1